| Symbol | BGLC |
|---|---|
| Name | BIONEXUS GENE LAB CORP |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Medical Specialities |
| Address | NO. 8 JALAN KERINCHI,THE VERTICAL BUSINESS SUITE II, UNIT 02, LEVEL 10, TOWER B, KUALA LUMPUR, 59200, Malaysia |
| Telephone | +60 122126512 |
| Fax | — |
| — | |
| Website | https://www.bionexusgenelab.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The companys non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis. Additional info from NASDAQ: |
New Form 10-K - BioNexus Gene Lab Corp <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001477932-26-002218 <b>Size:</b> 8 MB
Read moreNew Form NT 10-K - BioNexus Gene Lab Corp <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001477932-26-001877 <b>Size:</b> 21 KB
Read moreBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
Read moreBioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Read more(10% Negative) BioNexus Gene Lab Corp (BGLC) Announces Delay in commence Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment
Read moreNew Form DEF 14A - BioNexus Gene Lab Corp Filed: 2025-12-03 AccNo: 0001477932-25-008757 Size: 438 KB
Read moreBioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
Read moreBioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
Read more